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Abstract
NY-ESO-1  is  one  of  the  most  immunogenic  cancer  antigens  known  to  date,  eliciting
spontaneous immune responses in approximately 50% of patients with NY-ESO-1+ cancers.
Spontaneous CD4+ and CD8+ T cell  responses were  found in  patients  with  detectable
NY-ESO-1 serum antibody, indicating an integrated type of immune response induced by
NY-ESO-1+ malignancies.  A close association between spontaneous NY-ESO-1 immunity
and the HLA-DP4 allele was suggested in a recent study. To address these results,  we
assessed the  NY-ESO-1 antibody and HLA-DP4 status  of  102 patients  with  NY-ESO-1+
malignancies.  However,  no  correlation  between  HLA-DP4  and  NY-ESO-1  immunity  was
found. To explore the role of  HLA-DP4-restricted CD4+ T cells  in  cancer immunity,  we
established HLA-DP4- restricted NY-ESO-1-specific CD4+ T cell clones by limiting dilution
and repeated stimulation with  NY-ESO-1 peptide p157-170 from NY-ESO-1 seropositive
patients. A subset of CD4+ T cell clones was reactive with naturally processed NY-ESO-1
presented by autologous DCs that were pulsed with recombinant NY-ESO-1 protein, lysates
of NY-ESO-1-expressing tumor cell lines, or transduced with recombinant NY-ESO-1 viral
constructs in ELISPOT assays. Three different CD4+ T cell clones were used to mediate the
specific lysis of allogeneic HLA-DP4+ Epstein-Barr virus-transformed B cells (EBV-B) pulsed
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with NY-ESO-1 p157-170. The Th1 phenotype and effector functions of the CD4+ T cell
clones described here provide an important rationale for the activation of antigen-specific
CD4+ T cells along with CD8+ T cells in cancer vaccination strategies.
Introduction
NY-ESO-1 was identified by serological analysis of a recombinant cDNA expression library
(SEREX) from a squamous cell cancer of the esophagus (1). NY-ESO-1 is a cancer-testis
antigen that is expressed in different types of cancer, including hematological malignancies,
and in normal germ cells (2, 3, 4, 5). Spontaneous humoral and cellular immune responses
against NY-ESO-1 are detected in approximately 50% of patients with NY-ESO-1-expressing
cancers (6, 7) and are strictly dependent on the presence of NY-ESO-1+ disease. Changes
in NY-ESO-1-specific immune responses are closely correlated with the clinical development
of NY-ESO-1+ cancers (7, 8).
We identified a number of NY-ESO-1 epitopes recognized by CD4+ and CD8+ T cells that
are used to monitor spontaneous and vaccine-induced T cell responses against NY-ESO-1
(9, 10, 11, 12). Spontaneous NY-ESO-1-specific CD4+ and CD8+ T cell responses were
found exclusively in patients with detectable NY-ESO-1 antibody (13, 14, 15, 16, 17). Since
CD8+ T cells are considered the most potent effectors controlling cancer growth in vivo, the
majority of clinical cancer vaccine studies have focused on the induction of antigen-specific
CD8+ T cell responses (18, 19, 20). The role of MHC class II-restricted CD4+ T cells in
mediating tumor regression in vivo, however, has been less extensively studied. A number
of  studies have indicated that antigen-specific  CD8+ T cell  responses were significantly
enhanced and maintained over extended periods of time in the presence of CD4+ T helper
cells (21, 22, 23, 24).
Integrated  spontaneous  immune  responses  against  NY-ESO-1  that  involve  cellular  and
humoral  effectors  of  the immune system (13,  16)  are  often  observed  in  patients  with
advanced NY-ESO-1-expressing cancer. Therefore, NY-ESO-1 may be considered a model
system for  studying the correlation between immune response parameters  and defined
patient  and  disease  characteristics,  such  as  tumor  type,  extent  of  disease,  HLA  type,
antigen expression levels, and intratumoral localization of CD4+ and CD8+ T cells. A recent
study suggests that HLA-DP4 is closely associated with spontaneous NY-ESO-1 immunity
(11). To address this observation, we assessed the NY-ESO-1 serum antibody and HLA-DP4
status of 102 patients with NY-ESO-1-expressing cancers. To better understand the role of
NY-ESO-1-specific  CD4+  T  cells  in  orchestrating  integrated  immune  responses  against
NY-ESO-1, we established NY-ESO-1-specific, HLA-DP4-restricted CD4+ T clones from two
HLA-DP4+  patients  with  detectable  NY-ESO-1  antibody  and  characterized  these  with
respect  to phenotype,  pattern of  antigen recognition,  and effector  function.  The results
provide important perspectives for new strategies of cancer vaccination focusing on the
induction of integrated immune responses against defined cancer antigens in vivo.
Results
Lack of correlation between HLA-DP4 status and spontaneous NY-ESO-1 immunity
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We tested 102 patients with advanced cancers of different types that expressed NY-ESO-1
for the presence of NY-ESO-1 serum antibody and the HLA-DP4 allele. Fifty patients were
NY-ESO-1  antibody  positive,  and  52  were  NY-ESO-1  antibody  negative.  The  NY-ESO-1
antibody-positive  and  -negative  patients  were  comparable  with  respect  to  previous
treatments,  extent  of  disease,  metastatic  sites,  and  duration  of  metastatic  disease.
Seventy-nine  patients  were  HLA-DP4-positive  and  23  were  HLA-DP4-negative.  Of  79
HLA-DP4-positive patients, 39 were NY-ESO-1 antibody positive, and 40 were NY-ESO-1
antibody negative. Of 23 HLA-DP4-negative patients, 11 were NY-ESO-1 antibody positive,
and  12  were  NY-ESO-1  antibody  negative.  In  this  extended  analysis,  we  found  no
correlation between HLA-DP4 status and the presence of  spontaneous NY-ESO-1 serum
antibody (Table 1).
Table 1
NY-ESO-1 antibody and HLA-DP4 status of patients with NY-ESO-1-expressing
cancers
CD4+ and CD8+ NY-ESO-1-specific T cell responses
CD4+ and CD8+ T cells obtained from two NY-ESO-1 antibody-positive patients (NW1454
and NW1662) and from two NY-ESO-1 antibody-negative patients (NW1045 and NW1691)
were stimulated separately with autologous CD4- CD8- PBMCs, which were either pulsed
with NY-ESO-1 peptide p157-170 or transduced with NY-ESO-1 recombinant adenovirus
(Ad2/ESO). After 2-3 weeks of presensitization, CD4+ effector cells were tested for the
specific  recognition  of  the  NY-ESO-1  epitope  p157-170  presented  by  the  allogeneic
HLA-DP4+  NW1539-EBV-B  cell  line.  CD8+  effector  cells  were  tested  for  the  specific
recognition of the NY-ESO-1 epitope p157-165 presented by T2 cells in ELISPOT assays.
Strong NY-ESO-1-specific  CD4+ and CD8+ T cell  responses were induced in  NY-ESO-1
antibody-positive  patients  by  presensitization  with  NY-ESO-1  p157-170  and  Ad2/ESO,
whereas  no  reactivity  was  observed  in  NY-ESO-1 antibody-negative  patients  (Figure  1,
panels a and b). Efficient stimulation of CD8+ T cells was achieved using the HLA-DP4-
restricted  NY-ESO-1  peptide  p157-170,  which  includes  the  HLA-A2-restricted  NY-ESO-1
epitopes  p157-165  and  p157-167,  as  documented  in  ELISPOT  assays  against  T2  cells
pulsed with NY-ESO-1 p157-165 and p157-167 (Figure 1c).
Figure 1
Induction  of  NY-ESO-1-specific  CD4+  and  CD8+  T  cell  responses  after  in  vitro
presensitization with NY-ESO-1 p157-170 or Ad2/ESO.  CD4+ and CD8+ T cells  were
presensitized  with  (a)  NY-ESO-1  p157-170  or  (b)  Ad2/ESO.  Two  patients,  NW1454  and
NW1691, showed nonspecific reactivity against the irrelevant Melan A peptide p29-37 (white
bars)  after  Ad2/ESO stimulation (a  and b).  (c)  CD8+ T cell  responses were induced after
presensitization  with  NY-ESO-1  p157-170  against  the  stimulating  peptide  (black  bar),  and
against  T2  cells  pulsed  with  NY-ESO-1 p157-165 (checkered  bars)  and  p157-167 (vertical
stripes). No significant reactivity was observed against the irrelevant Melan A peptide p29-37
(white bars) or against T2 cells alone (horizontal stripes).
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Generation of NY-ESO-1-specific, HLA-DP4-restricted CD4+ T cell clones
CD4+  T  cells,  obtained  from  the  NY-ESO-1  antibody-positive  patients  NW1454  and
NW1662, were presensitized with NY-ESO-1 peptide p157-170 and further stimulated under
limiting dilution conditions. Four NY-ESO-1-specific CD4+ T cell clones were obtained from
patient NW1454, and 34 were obtained from patient NW1662. All CD4+ T cell clones were
tested for the specific recognition of NY-ESO-1 p157-170 in the context of four allogeneic
HLA-DP4-positive (NW1539-EBV, MZ070782, NW115-EBV, MZ1802-EBV) and two HLA-DP4-
negative (Ducaf-EBV, MZ1851-EBV) EBV-B cell lines. Reactivity against NY-ESO-1 p157-170
was documented for all of the CD4+ T cell clones in the context of HLA-DP4. Figure 2 shows
a representative experiment with the CD4+ T cell clone NW1662-CD4-12.
Figure 2
NY-ESO-1 p157-170-specific CD4+ T cell reactivity is restricted by HLA-DP4. The CD4+
T cell clone NW 1662-CD4-12 was tested against a panel of HLA-DP4-positive and HLA-DP4-
negative allogeneic EBV-B cell lines pulsed with NY-ESO-1 p157-170 (black bars) in ELISPOT
assays.  NY-ESO-1  p157-170-specific  reactivity  was  documented  against  peptide-pulsed
HLA-DP4+ EBV-B cells only. The white bars represent the background reactivity against EBV-B
cells alone.
Subsequently, the reactivity of these CD4+ T cell clones against graded doses of NY-ESO-1
p157-170  added  to  EBV-B  target  cells  was  evaluated.  Figure  3  shows  that  peptide
concentrations between 600 ng/ml (NW1662-CD4-12) and 3000 ng/ml (NW1662-CD4-54)
were required to achieve half-maximal reactivity with the CD4+ T cell clones tested.
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Figure 3
Reactivity  of  HLA-DP4-restricted  NY-ESO-1-specific  CD4+  T  cells  clones  against
different concentrations of NY-ESO-1 p157-170. Seven CD4+ T cell clones obtained from
patients  NW1454  and  NW1662  were  tested  against  different  concentrations  of  NY-ESO-1
p157-170 in ELISPOT assays. Depending upon the interclonal avidity, different levels of peptide
concentration are required for detectable reactivity with the respective CD4+ T cell clone.
Recognition of naturally processed NY-ESO-1
To confirm the HLA-DP4-restricted NY-ESO-1 p157-170 reactivity of CD4+ T cell  clones
against  naturally  processed  NY-ESO-1  epitopes,  autologous  DCs,  either  pulsed  with
recombinant  NY-ESO-1 protein  or  SSX protein  as  a  control,  or  infected  with  Ad2/ESO,
vaccinia/NY-ESO-1 recombinant virus (v.v. ESO) or wild-type vaccinia virus (v.v. WT) as a
control, were used as target APCs in ELISPOT assays. Three of four NW1454-CD4 clones
and two of four NW1662-CD4 clones reacted with autologous DCs pulsed with recombinant
NY-ESO-1 protein, whereas only one of these, NW1662-CD4-2, reacted with Ad2/ESO- or
v.v.  ESO-infected  autologous  DCs.  Autologous  DCs  pulsed  with  control  SSX  protein  or
transduced  with  v.v.  WT  were  not  recognized  (Figure  4a).  Clone  NW1662-CD4-2  was
further tested for recognition of autologous DCs pulsed with lysates of NY-ESO-1-positive
and NY-ESO-1-negative melanoma cell lines. As shown in Figure 4b, reactivity was only
documented against DCs pulsed with lysates of the NY-ESO-1-expressing tumor cell lines
NW-MEL-38 and SK-MEL-37.
Figure 4
Recognition of naturally processed NY-ESO-1.  (a) A panel of CD4+ T cell  clones were
tested in ELISPOT assays against autologous DCs pulsed with recombinant NY-ESO-1 protein
(black bars)  or  irrelevant recombinant SSX protein (white bars),  or  infected with Ad2/ESO
(horizontal stripes), v.v. ESO (checkered bars), or v.v. WT (gray bars). (b) CD4+ T cell clone
NW 1662-CD4-2 was tested for  specific  recognition  of  autologous DCs pulsed with  lysates
prepared  from  NY-ESO-1-positive  (NW-MEL-38  and  SK-MEL-37)  or  NY-ESO-1-negative
(NW-MEL-8) melanoma cell lines in ELISPOT assays.
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Cytotoxicity of NY-ESO-1-specific HLA-DP4-restricted CD4+ T cell clones
Three of the seven CD4+ T cell clones that were tested lysed the NY-ESO-1 p157-170-
pulsed HLA-DP4+ EBV-B cell line NW-1539-EBV efficiently; Figure 5a shows representative
results  of  two  different  CD4+ T  cell  clones.  In  addition,  T  cell  clone  NW1454-CD4-68
showed significant lytic activity against the NY-ESO-1-expressing HLA-DP4+ melanoma cell
lines  NW-MEL-38,  NW-MEL-634,  and  NW-MEL-450  after  treatment  with  100  U/ml
IFN-gamma, but not against the NY-ESO-1-negative melanoma cell line NW-MEL-8 or the
HLA-DP4-negative melanoma cell lines Mel624 and SK-MEL-29 (Figure 5b).
Figure 5
NY-ESO-1-specific cytotoxic reactivity of CD4+ T cell clones. (a) The CD4+ T cell clones
NW 1454-CD4-68 (triangles) and NW 1662-CD4-2 (squares) were tested against the allogenic
HLA-DP4+  EBV-B  cell  line  NW1539-EBV-B,  either  pulsed  with  NY-ESO-1  p157-170  or  not
(closed and open symbols, respectively) in a 4-h chromium release assay at E/T ratios of 90,
30, 10, and 1:1. (b) The CD4+ T cell clone NW 1454-CD4-68 was tested against the HLA-DP4+
NY-ESO-1-positive melanoma cell lines NW-MEL-38, NW-MEL 634, and NW-MEL-450, against
the  NY-ESO-1-negative  melanoma  cell  line  NW-MEL-8,  and  against  the  HLA-DP4-negative
melanoma cell line SK-MEL-29 in a 4-h chromium release assay.
Immunophenotyping of NY-ESO-1-specific HLA-DP4-restricted CD4+ T cell clones
Immunophenotyping of the CD4+ T cell clones showed a CD4+ CD25- CD8- phenotype for
all clones. After restimulation with NY-ESO-1 p157-170, all the CD4+ T cell clones were
negative for the suppressor marker CTLA-4 and positive for the activation marker CD69
(data not shown).
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Discussion
NY-ESO-1  is  one  of  the  most  immunogenic  cancer  antigens,  leading  to  spontaneous
humoral and cellular immune responses in approximately 50% of patients with NY-ESO-
1-expressing malignancies (1, 7, 8, 13, 14). Much attention has been paid to monitoring
spontaneous and vaccine-induced NY-ESO-1-specific CD8+ T cell responses, which directly
mediate the lysis of antigen-expressing tumor cells in vivo (16, 18, 25). However, several
studies  have  indicated  that  active  immunization  may  be  made  more  efficient  by  the
simultaneous stimulation of antigen-specific CD4+ T cells (21, 26). A number of NY-ESO-1
peptide epitopes presented by different MHC class II molecules have been identified and
can be used to explore the role of NY-ESO-1-specific CD4+ T cells in the induction and
maintenance of antibody and CD8+ T cell responses against NY-ESO-1 (9, 10, 11, 12).
Spontaneous immunity against NY-ESO-1 was found to be associated with a more favorable
clinical  outcome  in  a  number  of  patients  analyzed  over  an  extended  period  of  time,
suggesting that NY-ESO-1 immunity may play a role in the control of cancer growth in vivo.
A relationship between spontaneous NY-ESO-1 immunity and the presence of the HLA-DP4
allele had been suggested in a previous study of 17 patients, in which 16/17 NY-ESO-1
antibody-positive patients expressed the HLA-DP4 allele (11).  This  relationship  was not
confirmed  in  our  analysis  of  102  patients  with  NY-ESO-1-expressing  cancers.  Of  79
HLA-DP4+  patients,  NY-ESO-1  antibody  was  detected  in  39  patients  (49.8%).  Of  23
HLA-DP4- patients, NY-ESO-1 serum antibody was found in 11 (47.8%).
To further characterize the phenotype and different effector functions of HLA-DP4-restricted
NY-ESO-1-specific CD4+ T cells, we generated CD4+ T cell  clones from two HLA-DP4+,
NY-ESO-1  antibody-positive  patients.  The  majority  of  CD4+  T  cell  clones  tested  were
reactive  with  processed  recombinant  NY-ESO-1  protein,  and  one  CD4+  T  cell  clone,
NW1662-CD4-2, reacted with autologous DCs pulsed with a lysate of NY-ESO-1-expressing
melanoma cells and with APCs virally transduced with NY-ESO-1, indicating a less efficient
processing of MHC class II-presented epitopes after viral gene transfer.
The effector functions of NY-ESO-1-specific CD4+ T cell clones were further characterized in
cytotoxicity assays. A subset of CD4+ T cell clones was tested for specific lysis of HLA-DP4+
APCs  pulsed  with  NY-ESO-1  p157-170,  and  of  NY-ESO-1-expressing  tumor  cell  lines.
Specific lysis of peptide-pulsed APCs was demonstrated for three CD4+ T cell clones, and
one of them (NW1454-CD4-68) also lysed the NY-ESO-1-expressing HLA-DP4+ melanoma
cell lines NW-MEL-38, NW-MEL-634, and NW-MEL-450 after treatment with IFN-gamma.
The central role of CD4+ T cells in the regulation of antibody and CD8+ T cell responses is
well established. Influenced by different cytokine profiles, CD4+ T cells may be modulated
toward helper or suppressor functions, as is indicated by the expression of different surface
markers (21, 27, 28). The NY-ESO-1-specific CD4+ T cell clones established in this study
were characterized by the CD4+ CD25- CD8- phenotype. CD4+ CD25+ suppressor T cells,
which are known to have downregulating effects on antigen-specific CD8+ T cell responses
(29, 30), were not identified, possibly as a result of the culture conditions. A subset of the
NY-ESO-1-specific CD4+ T cell clones that were generated exhibited strong lytic reactivity
against NY-ESO-1 p157-170-pulsed APCs and NY-ESO-1-expressing HLA-DP4+ melanoma
cell lines, making them attractive effectors for cancer immunotherapy. New strategies for
cancer vaccination, including protein, DNA, and recombinant viral vector constructs, focus
on the induction of integrated immune responses involving specific CD4+ and CD8+ T cells.
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Monitoring vaccine-induced immune responses will provide new insights into the interplay
between CD4+ T cells  and other  specific  effectors  of  the immune system and to  their
capacity to directly modulate the clinical development of disease in cancer patients.
Abbreviations
Ad2/ESO,  NY-ESO-1  recombinant  adenovirus;  EBV-B,  Epstein-Barr  virus-transformed  B
cells; v.v. ESO, vaccinia/NY-ESO-1 recombinant virus; v.v. WT, wild-type vaccinia virus
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Materials and methods
Patients
We typed 102 patients with metastatic NY-ESO-1-expressing cancers of different kinds for
the  presence  of  the  HLA-DP4  allele  and  tested  them  for  detectable  NY-ESO-1  serum
antibody using Western blot assays. Of these, four HLA-A2+ DP4+ patients were selected
for  the evaluation of  NY-ESO-1-specific  CD4+ and CD8+ T cell  responses.  At  the time
lymphocytes  were  collected  for  analysis,  two  patients  (melanoma patient  NW1454 and
non-small cell lung cancer patient NW1662) had detectable NY-ESO-1 serum antibody and
NY-ESO-1-specific CD8+ T cell reactivity, and two patients (melanoma patient NW1045 and
ovarian cancer patient NW1691) were NY-ESO-1 antibody negative.
Expression of NY-ESO-1 in tumor tissues
Expression of  NY-ESO-1  mRNA in  tumor  specimens  frozen  immediately  after  biopsy  at
-80°C was assessed by RT-PCR, using PCR conditions and primers as previously described
(1).
NY-ESO-1 serum antibody
NY-ESO-1  serum  antibody  was  assessed  by  standard  Western  blot,  using  NY-ESO-1
recombinant protein purified from Escherichia coli as described (7, 13).
Cell lines
EBV-B cells were derived from PBMCs obtained from individuals of different HLA types using
culture supernatant from the EBV-producing B95-8 cell line. EBV-B cell lines and the mutant
TAP-deficient lymphoblastoid cell line T2 (CEMx721.174.T2) were maintained in RPMI 1640
medium supplemented with 10% FCS, L-asparagine (50 mg/l), L-arginine (24 mg/l), and
L-glutamine (300 mg/l) as described (13). The EBV-B cell lines MZ070782 and DUCAF were
a kind gift from Dr. Ghislaine Sterkers, Hopital Robert Debre, Paris, France.
The  NY-ESO-1-expressing  melanoma cell  lines  NW-MEL-38,  NW-MEL-450,  NW-MEL-634,
SK-MEL-29,  Mel624,  and  SK-MEL-37,  and  the  NY-ESO-1-negative  melanoma  cell  line
NW-MEL-8, were established from surgically resected melanoma metastases and cultured in
DMEM  (Life  Technologies,  Gaithersburg,  MD,  USA)  supplemented  with  10%  FCS,
L-asparagine (50 mg/l),  L-arginine (24 mg/l),  and L-glutamine (300 mg/l) as described
(13). For the cytotoxicity assay, the tumor cells were pretreated with IFN-gamma (100
U/ml, Bioferon, Laupheim, Germany) for 24 h.
Peptides
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The HLA-DP4-restricted NY-ESO-1 peptide p157-170 (SLLMWITQCFLPVF) was selected to
analyze the CD4+ T cell response to NY-ESO-1 in HLA-DP4+ patients (31). Two HLA-A2-
restricted  NY-ESO-1  peptides,  p157-167  (SLLMWITQCFL)  and  p157-165  (SLLMWITQC),
were selected to analyze the CD8+ T cell response to NY-ESO-1 (13). The HLA-A2-binding
Melan A peptide p29-37 (GILTVILGV) was included for control purposes. All peptides were
synthesized by Multiple Peptide Systems (San Diego, CA, USA) with a purity of >90%, as
determined by reverse-phase HPLC.
Viral constructs
Adenovirus encoding the full-length NY-ESO-1 cDNA (Ad2/ESO) was provided by Genzyme
Corporation (Framington, MA, USA), and v.v. WT and v.v. ESO were provided by Therion
Biologics (Cambridge, MA, USA). Viral constructs were used for the preparation of NY-ESO-
1-expressing APCs as described (14).
Presensitization of CD4+ and CD8+ effector T cells
CD4+ and CD8+ T lymphocytes were separated from PBMCs by antibody-coated magnetic
beads  (MiniMACS,  Miltenyi  Biotec,  Auburn,  CA,  USA)  and  seeded  into  24-well  plates
(Greiner) at 5 x 105 cells/well in RPMI 1640 medium supplemented with 10% human serum
and L-glutamine (300 mg/l). PBMCs depleted of CD4+ and CD8+ T cells were either pulsed
with peptide (10 µg/ml) or infected with recombinant Ad2/ESO at 1000 infection units/cell
and used as APCs. These APCs were then irradiated and added to plates containing CD4+ or
CD8+ T cells at a concentration of 1 x 106 cells/well. IL-2 (2.5 ng/ml, Biotest, Dreieich,
Germany) and IL-4 (10 U/ml, Strathmann Biotech, Hannover, Germany) were added to
CD4+ T cell cultures, and IL-2 (2.5 ng/ml) was added to CD8+ T cell cultures (16).
Generation of NY-ESO-1-specific CD4+ T cell clones
NY-ESO-1-specific CD4+ T cell clones were obtained from limiting dilution cultures. Selected
CD4+ T cells were stimulated with irradiated autologous APCs pulsed with the HLA-DP4-
restricted NY-ESO-1 peptide p157-170 (10 µg/ml) in the presence of irradiated HLA-DP4+
EBV-B cells as feeder cells, and recombinant interleukin-2 (rIL-2) at 10 ng/ml and rIL-4 at
10 U/ml. Clones were maintained by weekly stimulation with irradiated HLA-DP4+ EBV-B
cells pulsed with NY-ESO-1 peptide p157-170 (10 µg/ml) and supplemented with rIL-2 and
rIL-4 (10 ng/ml and 10 U/ml, respectively).
Antigen-presenting target cells
DCs were generated from plastic-adherent peripheral blood monocytes that were cultured
for 6 d in the presence of IL-4 (1000 U/ml) and GM-CSF (1000 U/ml, Leukomax, Sandoz,
Nurnberg,  Germany).  On day 6 of  in  vitro  culture,  APCs were treated with  IL-4 (1000
U/ml), IL-6 (1000 U/ml), IL-1-beta (10 ng/ml), TNF-alpha (10 ng/ml, all  obtained from
Pharma Biotechnologie, Hannover, Germany), GM-CSF (1000 U/ml), and prostaglandin/E2
(1 µg/ml, Sigma Chemical, St. Louis, MO, USA).
PHA-transformed blast cells were generated by stimulation of CD4+ selected T cells with
PHA (1 µg/ml), and maintained in culture by repeated addition of IL-2 (10 ng/ml/wk).
DC or PHA blasts were either infected with Ad2/ESO or v.v. ESO at 1000 infection units/cell
at 37°C in 250 µl serum-free medium (X-VIVO-15, BioWhittaker, Walkersville, MD, USA), or
pulsed with peptides at 10 µg/ml, with recombinant proteins at 20 µg/ml, or with tumor cell
lysates prepared by three freeze-thaw cycles of 1 x 106 tumor cells, and cultured for 24 h.
APCs were then washed twice and used as targets in ELISPOT assays at 3 x 104 cells/well.
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ELISPOT assay
Flat-bottomed, 96-well nitrocellulose-lined plates (Millipore MultiScreen, Millipore, Bedford,
MA,  USA)  were  coated  with  IFN-gamma mAb (2  µg/ml,  1-D1K,  MABTECH,  Stockholm,
Sweden) and incubated overnight at 4°C. After washing with PBS, plates were blocked with
10% human AB serum for 1 h at 37°C. Typically, 2.5 x 104 CD4+ or CD8+ presensitized
effector T cells (see above) were incubated with 5 x 104 target cells, which were pulsed
with NY-ESO-1 peptide, recombinant protein, NY-ESO-1+ tumor cells lysates, or transduced
with  the  viral  vector  constructs  Ad2/ESO  or  v.v.  ESO.  Effector  and  target  cells  were
incubated for 20 h in RPMI medium 1640 supplemented with 10% human serum. After
incubation, the plates were thoroughly washed with 0.05% Tween 20 in PBS to remove
cells, and biotinylated secondary IFN-gamma mAb (0.2 µg/ml, 7-B6-1-biotin, MABTECH)
was added to each well. After incubation for 2 h at 37°C, the plates were washed and
developed with streptavidin-alkaline phosphatase (1 µg/ml,  MABTECH) for  1 h at  room
temperature.  After  washing,  substrate  (5-bromo-4-chloro-3-indolyl  phosphate  nitroblue
tetrazolium, Sigma) was added and the plates incubated for 5-10 min. After washing, the
dark-violet spots were counted under the microscope (14, 16).
Cytotoxicity assay
Cytotoxicity  against  NY-ESO-1 peptide-pulsed NW1539 EBV-B cells  and tumor cell  lines
before and after treatment with IFN-gamma was determined in standard chromium release
assays as described (32).
Immunophenotyping of CD4+ T cell clones
The  expression  of  cell  surface  markers  was  determined  by  FACS®  analysis  using
FITC-conjugated  anti-CD4,  anti-CD8,  anti-CD25,  anti-CD69,  and  anti-CTLA4  antibodies
(Beckman  Coulter,  Marseille,  France).  FITC-conjugated  antimouse  IgG1  was  used  as  a
negative control. 1-5 x 105 CD4+ T cells were labeled with the appropriate antibody in PBS
for 20 min (4°C), washed, and analyzed using a FACS® (Epics XL, Beckman Coulter).
Contact
Address correspondence to:
Prof. Dr. med. Elke Jäger
II. Medizinische Klinik
Hämatologie-Onkologie
Krankenhaus Nordwest
Steinbacher Hohl 2-26
60488 Frankfurt
Germany
Tel.: + 49 69 7601-3319
Fax: + 49 69 769932
E-mail: elke.jaeger@licr.org
LATEST PAPERS SEARCH for PAPERS Printer-friendly PDF Comment(s)
Cancer Immunity 4:15 (2004) http://archive.cancerimmunity.org/v4p15/041016.htm
13 von 14 15/10/15 11:54
Copyright © 2004 by Elke Jäger
Cancer Immunity 4:15 (2004) http://archive.cancerimmunity.org/v4p15/041016.htm
14 von 14 15/10/15 11:54
